SynBioBeta Speaker
Ling Li
ADM
Dir. Market Dev., Prec. Ferm.
Ling is the Director of Market Development for the Precision Fermentation group at ADM. In this role, she helps form partnerships across the value chain to scale precision fermentation opportunities. Prior to ADM, Ling has led business development and partnerships at various synthetic biology & precision fermentation start-ups, including Zymergen and C16 Biosciences, and she started her career in consulting at McKinsey & Company. Ling received her B.A. from Yale University and her MBA from Harvard Business School.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Ling
This Year
•
-
Biomanufacturing
Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS
Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.
Purchase Pass
Featuring
Jamie Bacher
Huxley Project
Principal
Ag-biotech veteran guiding tech to market.
Colby Adolph
Evonik
Sales Director
Fermentation scale-up connector: turning prototypes into manufacturable reality
Ling Li
ADM
Dir. Market Dev., Prec. Ferm.
Precision fermentation dealmaker bridging startups, scale, and brands
Eric Lee
Primient
Director, B&D - Fermentation
•
-
Biomanufacturing
Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS
Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.
Purchase Pass
Featuring
Jamie Bacher
Huxley Project
Principal
Ag-biotech veteran guiding tech to market.
Colby Adolph
Evonik
Sales Director
Fermentation scale-up connector: turning prototypes into manufacturable reality
Ling Li
ADM
Dir. Market Dev., Prec. Ferm.
Precision fermentation dealmaker bridging startups, scale, and brands
Eric Lee
Primient
Director, B&D - Fermentation
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
